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Introduction 1 
 2 
Prostate cancer is the second leading cause of cancer death in men and its incidence is 3 
expected to double by 2030 due to the aging global population [1]. The traditional 4 
diagnostic tests employed for detection of prostate cancer, namely prostate-specific antigen 5 
(PSA) and transrectal ultrasound (TRUS) guided biopsy lack sensitivity and specificity. The 6 
former is specific to the prostate gland but not to prostate cancer and the latter can miss 7 
approximately 30% of tumours and under-estimate tumour aggressiveness in around a third 8 
of cases [2, 3]. Imaging was initially employed for loco-regional staging with MRI and distant 9 
staging with CT or bone scintigraphy in patients with biopsy proven cancer. However, more 10 
recent advances in MR technology and the incorporation of functional sequences alongside 11 
anatomical imaging, termed multiparametric (mp) MRI, have improved our ability to both 12 
detect and characterize prostate tumours. MR imaging for biopsy guidance has been shown 13 
to improve accuracy of tumour detection and grading [4, 5], and MRI is now seen as an 14 
essential step prior to enrollment on active surveillance programmes [6]. As a result, some 15 
authors even suggest that MRI should replace TRUS biopsy as the initial diagnostic test for 16 
prostate cancer to enable guidance of subsequent biopsy [7].  17 
 18 
This change in practice is reflected in the updated 2014 NICE guidelines, which recommend 19 
more widespread use of MRI in the work-up of prostate cancer [6]. A recently published 20 
report from the National Prostate Cancer Audit revealed that while 99% of trusts in England 21 
that provide prostate cancer services have access to onsite MR imaging, only 75% provide 22 
mpMRI [8]. In addition, interpretation of prostate MRI entails a steep learning curve [9, 10] 23 
and requires regular reporting and audit in order to maintain reporting standards [11].  24 
 25 
The European Society of Urogenital Radiology (ESUR) in 2012 established clinical guidelines 26 
for the acquisition, interpretation and reporting of multi-parametric MRI of the prostate in 27 
order to facilitate a greater level of standardization and consistency [12]. These 28 
recommendations, popularly referred to as Prostate Imaging Reporting and Data System (PI-29 
RADS), were based on literature evidence and consensus expert opinion and were modelled 30 
on similar efforts in mammography (BI-RADS) that led to the transformation of breast 31 
cancer care. A number of studies have subsequently validated PI-RADS in certain research 32 
and clinical setting, however, experience has highlighted some limitations, in part due to 33 
technical improvements and also changes in clinical practice. A joint steering committee 34 
formed by the American College of Radiology (ACR), ESUR, and the non-profit organisation 35 
AdMeTech Foundation, have recently attempted to update and improve on the original 36 
proposals. PI-RADS Version-2 was officially launched at RSNA 2014, and is now available on-37 
line [13].  38 
 39 
Herein, we summarise the main features of PI-RADS v2, explore the background evidence 40 
that form the basis of the recommendations, and highlight the key differences with PI-RADS 41 
v1 for the benefit of those already familiar with the original. 42 
 43 
 44 
Format and scope 45 
 46 
The incorporation of the American College of Radiology into the consortium results in the 47 
subtle change to US-English, from the UK-English of the original European-based ESUR 1 
guidelines. The format is also fundamentally different, with the original being a 12-page 2 
article published in a peer-reviewed journal, whilst PI-RADS-v2 is a 55-page PDF document 3 
available on-line. This is necessary to meet the intended aims of being a “living” document 4 
that has scope to evolve with the accrual of clinical experience and scientific data; indeed 5 
some sections such as report templates and sample protocols remain listed as “under 6 
construction” on the earliest iteration. 7 
 8 
The mention of PI-RADS tends to invoke thoughts of the proposed scoring system, but in 9 
truth the original document was far more than this, with information on risk stratification in 10 
prostate cancer, enrolment criteria for active surveillance programmes, recommendations 11 
on MRI protocol parameters, and how to report findings. The format of v2 allows it to be 12 
even more comprehensive, with detailed background information including an overview of 13 
normal anatomy and benign findings, and a lexicon of terminology with relevant definitions. 14 
 15 
PI-RADS-v2 is more explicit in its scope and aims. It is designed to promote global 16 
standardization and diminish variation in the acquisition, interpretation, and reporting of 17 
prostate mpMRI examinations. Unlike the original document which struck a compromise by 18 
suggesting both “minimal” and “optimal” requirements, v2 only proposes to establish 19 
minimal technical parameters that should result in an acceptable mpMRI examination. A 20 
further aim that differs from v1 is to facilitate the use of MRI data for targeted biopsy, a 21 
reflection of the recent evolution of clinical practice [14]. Common to both, although more 22 
explicitly stated in v2, the guidelines are not intended for MRI application in the setting of 23 
suspected post-therapy recurrent prostate cancer, nor progression during surveillance, 24 
although they could be easily adopted for the latter. Unlike the original, separate protocols 25 
for “detection”, “staging” and “node and bone” are not suggested, rather a common 26 
protocol is presented, and MRI for evaluation of the skeletal system is explicitly not covered.  27 
 28 
A combined MRI and biopsy definition of “significant” prostate cancer is proposed based on 29 
recent clinical experience [15, 16]: Gleason score ≥7 (including 3+4 with prominent but not 30 
predominant Gleason 4 component), and/or volume ≥ 0.5cc, and/or extraprostatic 31 
extension (EPE). This is relevant to the stated aims of improving detection of significant 32 
cancer, whilst increasing confidence in calls of benign or insignificant disease, in order to 33 
reduce unnecessary biopsies and treatment. 34 
 35 
 36 
MRI Acquisition 37 
 38 
PI-RADS-v1 recommended the combination of high-resolution T2-weighted images (T2WI), 39 
and at least two functional MRI techniques, which could be diffusion-weighted imaging 40 
(DWI), dynamic contrast-enhance (DCE), or MR spectroscopy imaging (MRSI). In version-2 41 
MRSI is no longer recommended for PI-RADS assessment, with mpMRI consisting of 42 
anatomical imaging, DWI, and DCE alone. It is further noted that if functional imaging with 43 
both DWI and DCE is absent or inadequate, the MRI assessment should be limited to 44 
staging. 45 
 46 
Pre-procedure  47 
Minimum expected requirements are explicitly stated now for providing a relevant clinical 1 
history, namely recent PSA level and PSA history, family history, previous treatment, digital 2 
rectal examination findings, and biopsy status and result. PI-RADS-v1 recommended waiting 3 
at least 4-6 weeks between biopsy and MRI. The new version recommends waiting at least 6 4 
weeks when the purpose is for staging, but acknowledges that there may be no need for 5 
post-biopsy imaging delay if the primary purpose of the exam is to detect and characterize 6 
clinically significant cancer within the gland, based on the superior specificity of DWI 7 
utilizing high b-values [17]. 8 
 9 
Patient preparation 10 
It is acknowledged that at present there is a lack of consensus regarding issues of patient 11 
preparation. Antispasmodic agents are considered beneficial but not essential and use can 12 
be decided locally, based on considerations of cost, drug availability and potential for 13 
adverse drug reactions. An endorectal coil (ERC) is not routinely recommended, although 14 
with older generation 1.5T MRI systems, an ERC may be indispensable for achieving 15 
diagnostic quality imaging [18].  The patient should evacuate the rectum just prior to the 16 
MRI exam to minimise the presence of stool and rectal air which can lead to susceptibility 17 
artefact and distortion on DWI. If significant air is noted on initial imaging, consideration 18 
should be given to performing the remainder of the examination in a prone position or 19 
attempts made to decompress the rectum. Although in some centres abstention from 20 
ejaculation 72 hours prior to scanning is employed to maintain seminal vesicle distention, a 21 
benefit for this is not established and is therefore not recommended.  22 
 23 
MR Protocols  24 
In contradistinction to the original guidance, v2 proposes just one protocol for MR imaging 25 
of the prostate, with no separate parameters offered for 1.5T protocols. 3.0T is considered 26 
superior to 1.5T, however, both 1.5T and 3.0T can provide adequate and reliable diagnostic 27 
exams when acquisition parameters are optimized and appropriate contemporary 28 
technology is employed. 1.5T should be used for patients with implants that are MR 29 
conditional at 1.5T but not at 3.0T, or where artefact from implants such as hip 30 
replacements will compromise imaging at 3.0T.  31 
  32 
There is also a strong recommendation that the imaging plane angle, location, and slice 33 
thickness are identical for all sequences. If image quality of any sequence is suboptimal, 34 
measures should be taken to repeat the sequence. The technical parameters recommended 35 
for T2, DWI and DCE sequences are summarized in Table 1, a brief overview of the key 36 
points for each sequence and changes is given below.  37 
 38 
Anatomical imaging 39 
Axial T1W images remain essential to assess for biopsy-related haemorrhage. These can be 40 
with or without fat suppression and should match the other axial sequences, although lower 41 
spatial resolution may be employed. Multiplanar T2WI should incorporate the axial, sagittal, 42 
and coronal planes; the “detection” protocol in v1 only recommended axial and sagittal 43 
imaging. 3D axial acquisitions may be used, however, in‐plane resolution may be lower than 44 
the equivalent 2D acquisition and these should therefore be used as an adjunct to, rather 45 
than a replacement for 2D imaging.  46 
 47 
Diffusion-weighted imaging 1 
DWI should incorporate a minimum of two b‐values and a mono-exponential model of 2 
signal decay, which is in contrast to the original PI-RADS where at least 3 b-values were 3 
recommended, with prescribed values of 0, 100 and 800–1000 s/mm2. This is set as the 4 
minimum requirement and if only two b‐values are acquired, the lowest should be 50‐100 5 
sec/mm2 (not b-0) and the highest should be 800‐1000 sec/mm2. In addition, the acquisition 6 
of “high b‐value” images is recommended, utilising a b‐value of at least 1400 sec/mm2, or up 7 
to 2000 sec/mm2, if SNR remains adequate. The original v1 recommended using the ≥800 8 
sec/mm2 as the “high b-value” series for interpretation purposes. However, despite these 9 
changes, the recommendations for ADC maps essentially remain the same with exclusion of 10 
any b-0 data to avoid pseudo-perfusion effects [19], and utilizing a high b-value of no 11 
greater than 1000 s/mm2 for calculation purposes. 12 
  13 
Dynamic contrast-enhanced MRI  14 
PI-RADS-v2 now recommends a fat-suppressed sequence to improve lesion conspicuity; 15 
subtraction can be used as a replacement or as a post-processing adjunct in cases of biopsy-16 
related haemorrhage. The most widely used method of assessing DCE is visual assessment 17 
of each slice by cine loop or manually scrolling, and there is currently insufficient evidence 18 
to recommend the routine use of pharmacodynamic (PD) analysis. Parametric maps can be 19 
calculated depending on local preference, but any suspicious findings should always be 20 
confirmed on the source images. An injection rate of 2-3 ml/s should be employed, with a 21 
temporal resolution of <10 seconds and preferably <7 seconds in order to depict focal early 22 
enhancement. This differs from the original guidelines of a 15 seconds temporal resolution, 23 
with a higher temporal resolution of <10 s suggested when PD analysis is to be performed. 24 
Whilst version 1 stated the minimum length of acquisition post-injection in order to detect 25 
washout as being 5 minutes, v2 simply states a total observation time of ≥2minutes, this 26 
relates to the de-emphasis of PD analysis that requires longer acquisition periods for DCE. 27 
 28 
 29 
MRI Interpretation 30 
 31 
It is emphasised that the assigned PI-RADS-v2 score is based solely on mpMRI findings and 32 
does not take into account clinical factors that may be of key relevance such as PSA, clinical 33 
history, or previous biopsy results. As such reporters may choose to use a Likert scale of 34 
probability to reflect these factors (Figure 1). Typically an overall PI-RADS score of 4 or 5 35 
means a biopsy is recommended. Subtle changes have been made to the 5-point scoring 36 
systems for T2WI findings in the PZ and TZ and for diffusion-weighted imaging findings 37 
(Table 2). DCE-MRI has changed from a 5-point scale to simply being either “positive” or 38 
“negative”. Additionally, at the end of the document, example images are provided for all 39 
PI-RADS categories for each of the three sequences in both the PZ and TZ.  40 
 41 
The concept of a “dominant sequence” is formally introduced. DWI is the key sequence for 42 
the PZ, and T2WI predominates in the TZ. Simplified guidance tables help to emphasize this 43 
interpretation and how to assign the final PI-RADS-v2 score (Table 3), essentially the 44 
dominant sequence score is the final score for 1, 2, 4, or 5 and for scores of 3, the secondary 45 
sequence (DCE in PZ and DWI in TZ) may change the score from 3 to 4. The system proposed 46 
helps provide some clarity, as previous authors have used PI-RADS-v1 in a variety of ways: 47 
using a Likert system based on PI-RADS descriptors [20], employing a summed PI-RADS score 1 
from all sequences with a cut-off [21-23], or using an average score [24]. Early studies have 2 
already been performed assessing the PI-RADS-v2 system [25], and it will be interesting to 3 
test inter-observer variation and outcomes compared to final pathology. 4 
 5 
T2-weighted Scoring  6 
Anatomical imaging was previously the mainstay of prostate MRI and axial T2WI remains 7 
the key sequence for local staging, including extracapsular extension and seminal vesicle 8 
invasion, and for the assessment of the transition zone. If the T2WI PI-RADS score in the TZ 9 
is 3, this can be upgraded to a score of 4 if DWI, the secondary sequence, shows strong 10 
restricted diffusion (category 4, 5).  However, it is noted that diffusion is often reduced in 11 
BPH nodules so caution should be exercised in this setting. T2WI findings in the peripheral 12 
zone lack specificity, low signal can be due acute or chronic prostatitis, post-inflammatory 13 
scars and atrophy, haemorrhage, and previous treatment, as well as tumour [26]. As a 14 
result, DWI is the dominant sequence used in the PZ. It should be emphasized that in the 15 
normal PZ, it is unusual for diffusion to be very restricted in conditions other than cancer. 16 
 17 
The main change in the T2WI scoring system relates to category 4 and 5. Previously lesions 18 
needed to show either a suspicion for early (capsular bulging or broad contact) or 19 
established extra-capsular extension (ECE) to reach a score of 5. In the updated system, the 20 
criteria retain the latter, but replace the former with a size cut-off of 1.5 cm (Figure 2). Of 21 
note, the use of the terms “erased charcoal” to described TZ tumours and “organised chaos” 22 
to describe the normal transition zone appearance due to BPH on T2 have been dropped 23 
from the summary scoring system. These somewhat evocative terms are however retained 24 
within the text of the article and it is sensible for the reader to keep them in mind when 25 
interpreting the T2 sequences. The description of TZ tumours having a lenticular or “tear-26 
drop” shape [27] is retained. A formal definition of what constitutes category 3 findings is 27 
provided for PZ and TZ alongside the original article’s slightly ambiguous statement of not 28 
otherwise being in categories 1, 2, 4, or 5.   29 
 30 
Diffusion-weighted imaging Scoring  31 
Non-cancerous nodules of BPH can contain stroma or have a high cellular density and can 32 
therefore demonstrate restricted diffusion [28], thus DWI is the secondary sequence to T2 33 
for TZ interpretation. DWI is however the main sequence for interpretation of the PZ, with 34 
DCE the secondary sequence, thus a DWI score of 3 in the PZ can be upgraded to category 4 35 
if the matching DCE is positive. The scoring system for DWI in categories 2-5 has changed 36 
considerably compared to version 1 (Table 2). As with the T2WI scoring, the distinction 37 
between categories 4 and 5 is based on a size cut-off of 1.5cm or features of ECE, this offers 38 
consistency between the two dominant sequences. 39 
   40 
It is emphasized that absolute ADC values should be used with caution as these can vary 41 
substantially depending on the value and number of b-values selected, the magnet strength, 42 
the vendor, and inter-patient variability [29-31]. PI-RADS-v2 does however suggest that an 43 
ADC threshold of 750‐900 μm2/sec can be used for differentiation between benign and 44 
malignant prostate tissues in the PZ. It is also recommended that ADC maps are consistently 45 
viewed with the same contrast windowing, set to adequately portray clinically significant 46 
prostate cancers as markedly hypointense on ADC maps. Clearly these will need to be 47 
tailored to the particular scanner and advice from radiologists who have experience with a 1 
similar magnet may be helpful. In our experience, using a window width of 1400 μm2/sec 2 
and window level of 1400 μm2/sec sets the grey-scale range from 700 – 2100 μm2/sec, with 3 
potentially significant ADC values of <700 μm2/sec therefore appearing as “black”.  4 
 5 
Dynamic contrast-enhanced MRI Scoring  6 
The interpretation of DCE and the application of its results have changed significantly from 7 
version 1. Although the role of DCE-MRI appears downplayed, PIRADS-v2 explicitly states 8 
that DCE should be included in all prostate mpMRI examinations to avoid missing some 9 
small but significant tumours [32]. Additionally, in situations when one of the other 10 
sequences is non-diagnostic, DCE can be helpful in assessing risk. 11 
 12 
Considerable effort was previously expended in v1 looking at “curvology” of contrast wash-13 
in and wash-out from the prostate and prostatic lesions. Three curve patterns are described: 14 
Type I, progressive enhancement, Type II, plateau of enhancement, and Type III, contrast 15 
washout. Curve typing works well in breast imaging where Type I is considered benign (only 16 
8.9% of tumours demonstrate this pattern), Type II is intermediate probability, and a Type III 17 
curve is considered malignant (only 5.5% of benign lesions show this pattern) [33]. PI-RADS-18 
v1 endorsed the visual assessment of specific curve types along with focality and asymmetry 19 
of enhancement in order to create a 5-point DCE score. However, the enhancement 20 
characteristics of prostate show great heterogeneity: BPH nodules are often hypervascular 21 
(Figure 3), the absence of early enhancement usually adds little information, and diffuse 22 
enhancement can be seen in the setting of prostatitis. Furthermore, there is little evidence 23 
in the literature to support the qualitative use of curve types for identifying prostate cancer 24 
[34]. Indeed Hansford, et al [35] recently showed that despite good inter-observer 25 
agreement on curve-type assignment, curvology cannot reliably differentiate prostate 26 
cancer from benign prostate tissue, with the majority of tumours demonstrating Type 2 27 
enhancement curves (Figure 4).   28 
 29 
As a result, PI-RADS-v2 does not consider the type of curve important, with DCE only classed 30 
as “positive” in the presence of focal enhancement that corresponds to a suspicious finding 31 
on T2 and/or DWI. DCE is considered the secondary sequence for the PZ, and lesions scoring 32 
3 on DWI can be upgraded to category 4 overall if DCE is positive. DCE may also be helpful in 33 
prioritization when multiple lesions are present in the same patient, or for identification of 34 
the index lesion. Although DCE-MRI has no role to play in the transition zone in the presence 35 
of good quality T2WI and DWI, it can be utilized as a secondary sequence if DWI evaluation 36 
in part or all of the gland is technically compromised. 37 
 38 
Although DCE-MRI is often the key sequence for identifying recurrent disease after previous 39 
focal or whole-gland treatment [36-38], PI‐RADS v2 is specifically aimed at assessment of 40 
treatment naïve patients. 41 
 42 
Staging 43 
T2-weighted imaging is the key sequence for determining the “T-stage” of tumours. 44 
Distinction between T1 and T2 disease and their subsets is less important than determining 45 
organ-confined (T1-2 disease) versus extra-prostatic extension (T3a disease), seminal vesicle 46 
involvement (T3b), or invasion of the pelvic side wall or other organs (T4 disease). Although 47 
some work suggests DWI may help in the detection of ECE [39], this benefit may partially 1 
relate to more confident tumour localization; clearly initial identification of the tumour 2 
using anatomical and functional sequences is an aid to accurate staging. In version 1 extra-3 
prostatic involvement (T3a/b) was also scored on a five-point scale and, although a formal 4 
scale is no longer employed, the features to look for are retained. 5 
 6 
Imaging features suggesting extra-prostatic extension include overt ECE, capsular bulging or 7 
irregularity, broad capsular contact (>1.0 cm), filling in of the retroprostatic angle, and 8 
asymmetry or invasion of the neurovascular bundles. Recent work has demonstrated that 9 
the degree of tumour contact length with the capsule is a better predictor than both 10 
pathological tumour volume and clinical nomograms: capsular contact >2cm demonstrated 11 
an accuracy of 82% for predicting ECE, whereas with contact <1cm the chance of ECE was 12 
<5% [40]. 13 
 14 
The MRI features of seminal vesicle invasion (SVI) are low T2W signal, restricted diffusion, 15 
abnormal contrast enhancement, obliteration of the angle between the seminal vesicle and 16 
prostatic base, and demonstration of contiguous tumour extension. Three patterns of SVI 17 
have been described: Type I, direct spread along the ejaculatory ducts, Type II, direct 18 
invasion from tumour through the capsule into the seminal vesicles, and Type III, metastasis 19 
from a remote non-contiguous primary in the prostate. Ohori et al in 1993 demonstrated 20 
SVI as being Type I in 26%, Type II in 33%, combined Types I and II in 28%, and Type III in 21 
13% of cases [41]. A more recent study showed an almost equal split between Type I and II, 22 
but with no Type III disease [42]. Although the type of seminal vesicle invasion may not be 23 
clinically relevant and is not routinely reported by pathologists [43], it is worth noting the 24 
relative rarity of Type III involvement if the tumour is confidently identified in a location 25 
remote from the base or the confluence with the ejaculatory ducts at the verumontanum.  26 
 27 
Unlike version 1, there is no dedicated “nodes and bones” protocol, as the imaged 28 
population will be expected to have either organ-confined or locally advanced disease. At 29 
least one sequence should employ a field‐of‐view (FOV) that permits evaluation of lymph 30 
nodes up to the level of the aortic bifurcation. MRI assessment of lymph nodes remains 31 
limited to morphological features and size, with nodes >8mm in short axis regarded as 32 
suspicious. DWI is not considered a reliable discriminator between benignity and metastatic 33 
involvement; normal nodes can have an impeded diffusion due to their high cellularity, and 34 
lymph nodes have a relatively long T2 relaxation time and will therefore appear as high 35 
signal intensity structures on b-value DWI [44]. This latter property can be exploited by 36 
using the high b-value sequence as a means of identifying and mapping out nodes [45], 37 
which can then be evaluated on the anatomical sequences. The imaged bones should be 38 
reviewed for metastases, and again the high b-value imaging may aid conspicuity (Figure 5).  39 
 40 
 41 
MRI Reporting 42 
 43 
The original PI-RADS article stated the use of a structured reporting scheme was preferred. 44 
The benefits of proforma-type reporting have been championed [46], and this is consistent 45 
with the RSNA radiology reporting initiative for improving reporting practices. PI-RADS v2 46 
has provision for example template reports in Appendix I, but these remain “under 47 
construction”. 1 
 2 
Lesions with a PI-RADS score of 3, 4, or 5 should be reported, up to a maximum of four. The 3 
index (dominant) lesion should be identified. This is defined as the lesion with the highest 4 
PIRADS score, if this is assigned to two or more lesions, the index lesion should be the 5 
largest lesion, or the one that shows EPE. The minimum requirement is to report the largest 6 
dimension of a suspicious finding on an axial image, if the largest dimension is derived from 7 
the sagittal and/or coronal images, this measurement and plane should also be reported. 8 
Consistent with the predominant sequences previously described, PZ lesions should be 9 
measured on ADC maps and TZ lesions measured on T2W. Unless direct lesion volumetry is 10 
available, overall gland volume should be recorded using the ellipse formula (maximum AP 11 
diameter) x (maximum transverse diameter) x (maximum longitudinal diameter) x 0.52. 12 
 13 
Lesion location should be reported according to the sector map to enable localization of 14 
findings and as a visual aid for subsequent biopsy and/or treatment planning. Either a paper 15 
copy or scanned electronic version of the map should be used for recording. PI-RADS-v1 16 
suggested a minimum requirement of dividing the prostate into 16 regions, with an optimal 17 
requirement of 27 regions. The updated recommendations are 36 sectors for the prostate, 18 
with an additional two for the seminal vesicles and one for the external urethral sphincter.  19 
 20 
Although there was no diagrammatic representation in the original paper, the 21 
recommendations were based on the scheme proposed by Dickinson et al [47] and 22 
developed from earlier work by Villers, et al [48] and Haffner, et al [49]. Herein, the gland is 23 
separated into left and right and medial and lateral at the level of the apex, mid, and base. 24 
There is further division into anterior and posterior by the “17-mm line”, which is based on 25 
the likely reach of a 20 mm transrectal biopsy needle. An interim update by Barentsz, et al 26 
[50] proposed the 36-sector partition, with additional division of the anterior stroma levels 27 
into left and right and further splitting the transition zone into anterior and posterior above 28 
and below the 17-mm line. For PI-RADS v2, a new diagram has been drawn based on the 29 
earlier work, which now incorporates the central zone (Figure 6), but includes only 30 
alphabetic abbreviations in contradistinction to the alphanumeric labels of the earlier 31 
schemes.   32 
 33 
 34 
Conclusions 35 
PI-RADS version 2 offers a comprehensive overview of the role of multiparametric MRI for 36 
the initial assessment of prostate cancer (Table 4). The diagnostic work-up and treatment of 37 
prostate cancer continues to progress rapidly, and the nature of PI-RADS v2 as a “living” on-38 
line document will allow it to adapt and match this clinical evolution.  It is now the task of 39 
the imaging community to test the validity of PI-RADS v2 including its sensitivity and 40 
specificity for clinically significant disease, its reproducibility among readers with different 41 
experience levels and between centres, and its role in active surveillance decisions. As a 42 
living document, there is no doubt that version 3 is already in its earliest stages. 43 
 44 
 45 
 46 
  47 
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Tables 1 
 2 
• T2-weighted imaging (axial, sagittal, coronal planes) 
- Field-of-view: 12‐20 cm to encompass the entire prostate gland and seminal vesicles  
- 3 mm slice thickness, 0 mm gap  
- In-plane resolution: ≤ 0.7mm (phase) x ≤0.4mm (frequency) 
 
• Diffusion-weighted imaging (axial plane) 
- Free‐breathing spin echo EPI sequence combined with spectral fat saturation is recommended 
- Slice thickness to match T2WI   
- TE: ≤ 90 msec; TR : > 3000 msec 
- Field-of-view: 16‐22 cm 
- In plane dimension: ≤ 2.5mm phase and frequency 
- At least 2 b-values should be acquired in three orthogonal directions. If only 2 b-values are utilised, these 
should be 50‐100 s/mm2 (low) and 800‐1000 s/mm2 (high) 
- “High b‐value” acquisition with b‐1400 – 2000 s/mm2, depending on achievable quality of SNR 
- ADC map calculation: low b-value should be ≥50 sec/mm2, high b-value should be >800 s/mm2, up to a 
maximum of 1000 s/mm2 
 
• Dynamic contrast-enhanced MRI (axial plane) 
- Fat-saturated 2D or 3D T1 gradient echo (GRE) sequence; 3D is preferred  
- Slice thickness to match T2WI   
- Injection rate: 2‐3 ml/sec     
- TR / TE: <100msec / <5msec 
- In-plane dimension: ≤2mm X ≤2mm 
- Temporal resolution: ≤10 sec (<7 sec is preferred) 
- Pharmacodynamic analysis does not have to be performed 
 
Table 1. Acquisition protocols: Technical parameters 3 
 4 
 5 
Score  Criteria   
 
T2W for Peripheral Zone 
 
   1         Uniform high signal intensity 
   2         Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated  
   3         Heterogeneous signal intensity or non‐circumscribed, rounded, moderate hypointensity. Or  
              other not in categories 1/2 or 4/5 
              [Intermediate, not 1/2 or 4/5] 
   4         Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and  
              <1.5 cm in greatest dimension 
               [No size stated] 
   5          Same as 4 but ≥1.5cm in greatest dimension or definite ECE/invasive behavior 
               [Broad >1.5 cm capsule contact] 
     T2W for Transition Zone 
 
   1          Heterogeneous intermediate SI 
                [Used terms well-defined margins and “organised chaos”] 
   2          Circumscribed hypointense or heterogeneous encapsulated nodule(s) (BPH) 
               [Used well-marginated] 
   3          Heterogeneous signal intensity with obscured margins. Or other not in categories 1/2 or 4/5 
               [Intermediate, not 1/2 or 4/5] 
   4          Lenticlular or non‐circumscribed, homogeneous, moderately hypointense, and <1.5 cm in  
               greatest dimension 
               [No size stated. Used term “erased charcoal sign”]  
   5          Same as 4, but ≥ 1.5cm in greatest dimension or definite ECE /invasive behavior 
               [Involving the anterior fibromuscular stroma or the anterior horn of the PZ]  
Diffusion-weighted Imaging 
 
   1          No abnormality (i.e. normal) on ADC and high b‐value DWI 
   2          Indistinct hypointense on ADC 
               [Also diffuse hyper SI on ≥b800 image; no focal features] 
   3          Focal mildly/moderately hypointense on ADC and isointense/ mildly hyperintense on high  
               b‐value DWI 
               [Intermediate, not 1/2 or 4/5] 
   4          Focal markedly hypontense on ADC and markedly hyperintense on high b‐value DWI; <1.5cm in           
               greatest dimension 
              [Iso-intense on high b-value. No size stated] 
   5          Same as 4 but ≥1.5cm in greatest dimension or definite ECE / invasive behaviour 
                [Focal, hyper SI on the high b-value images with reduced ADC] 
Dynamic contrast-enhanced MRI 
 
   -          No early enhancement   OR 
              Diffuse enhancement not corresponding to a focal finding on T2 and/or DWI   OR 
              Focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI 
   +         Focal   AND  
              Earlier than or contemporaneously with enhancement of adjacent normal prostatic tissues  AND 
              Corresponds to suspicious finding on T2 and/or DWI 
Table 2. PI-RADS v-2 scoring systems. Differences from version 1 stated in parentheses; ECE 1 
= Extra-Capsular Extension, BPH = Benign Prostatic Hypertrophy, ADC = apparent diffusion 2 
co-efficient, DWI = Diffusion-Weighted Imaging 3 
 4 
 5 
Peripheral Zone 
DWI score 
(Dominant sequence) 
DCE score 
(Secondary sequence) 
T2WI score Overall PIRADS-v2 
score 
1 Any Any 1 
2 Any Any 2 
3 - ve Any 3 
3 + ve Any 4 
4 Any Any 4 
5 Any Any 5 
Transition Zone 
T2WI score 
(Dominant sequence) 
DWI score 
(Secondary sequence) 
DCE score Overall PIRADS-v2 
score 
1 Any Any 1 
2 Any Any 2 
3 ≤4 Any 3 
3 5 Any 4 
4 Any Any 4 
5 Any Any 5 
Table 3. Guidance for assignment of overall PIRADS-v2 score  1 
 2 
 3 
• Format and scope 
- Intended as a “living” web-based document that will evolve with clinical practice 
- Explicitly only for initial MRI examination, not for follow-up in Active Surveillance or assessment 
post-treatment 
- Only proposes minimal technical parameters for an acceptable mpMRI examination, with the 
previous “optimal” parameters omitted 
• MRI Acquisition 
- Spectroscopy is no longer used for PIRADS assessment 
- No delay in MRI post-biopsy if the primary purpose is to detect and characterize “clinically 
significant” cancer 
 - Anti-peristaltic medications recommended but no longer considered essential 
- Single MRI protocol recommended, in contrast to original “detection”, “staging” and “node and 
bone” protocols 
• Interpretation 
- PI-RADS-v2 score is based solely on mpMRI findings and does not take into account clinical factors  
- Typically an overall PI-RADS score of 4 or 5 means a biopsy should be considered in this region, 
but the score does not explicitly state recommendations for management 
- DWI is the dominant sequence for interpretation in the PZ, T2WI predominates for TZ assessment 
- The secondary sequences are DCE in the PZ and DWI in the TZ. If the primary sequence has a PI-
RADS score of 3, the secondary sequence may change the category to 4. 
- For category 5 assessment in both the transition zone and peripheral zone, lesions must be more 
than 1.5 cm in size or demonstrate extraprostatic or invasive changes 
- ADC maps should be consistently viewed with the same contrast windowing. Absolute ADC values 
should be interpreted with caution. 
- For DCE-MRI interpretation, the presence of focal enhancement is important rather than the type 
of curve 
- T2WI remains key for the purposes of staging 
• Reporting 
- Structured reports are recommended. Examples are yet to be provided 
- Lesions with an overall PI-RADS score ≥3 should be reported, up to a maximum of 4 lesions, with 
the index lesion identified 
- The maximal axial dimensions of a lesion should be reported using the ADC map as reference for 
PZ lesions and T2WI for TZ lesions 
- Sector Maps consist of 36 prostatic regions, compared to 16 (minimal) and 27 (optimal) in v1. The 
gland is again divided into anterior and posterior by the “17-mm line”, based on the likely reach of 
a 20 mm transrectal biopsy needle 
- The new schema incorporates the central zone and includes only alphabetic rather than 
alphanumeric abbreviations 
Table 4. Summary of key differences proposed in PIRADS-v2 4 
  5 
Figure legends 1 
 2 
 3 
Figure 1. Importance of clinical context 4 
60 year old referred for raised PSA. Axial T2WI (A) demonstrates a focal lesion in the left mid 5 
PZ (arrows), with matching restricted diffusion (B); PI-RADS score 4. Subsequent 6 
transperineal fused US-MRI targeted-biopsy is planned (C), with sagittal US image 7 
confirming needle placement in the lesion (D). Histology confirms high-grade PIN. MRI 8 
repeated at 18 months shows no change in the previously sampled lesion (E, F). Although 9 
the PI-RADS score is based solely on mpMRI findings and remains 4, when taking account of 10 
clinical context, the report conclusion would more appropriately state that clinically 11 
significant cancer is unlikely to be present. 12 
 13 
 14 
 15 
Figure 2. Differences in T2 scoring for high probability targets 16 
77 year-old patient with a PSA of 17 ng/ml. A: T2WI imaging shows a large (2.5 x 1.5 cm) 17 
lesion centred in the left transition zone at the level of the mid gland (arrow), with matching 18 
restricted diffusion (B, C). PI-RADS v1 scores: 4 for T2 as no features of ECE and no broad 19 
capsular contact, 5 for DWI. PI-RADS v2 overall score 5: T2 is the dominant sequence and 20 
the lesion is >1.5 cm, despite no features of ECE. Subsequent targeted biopsy confirms 21 
Gleason 4+5 disease (90% core involvement) in the left medial mid gland and Gleason 5+5 22 
(60% involvement) in the left posterior lateral gland. 23 
 1 
 2 
 3 
Figure 3. False-positive DCE result, correctly classed as low probability for tumour with PI-4 
RADS v2 criteria 5 
63 year-old man, serum PSA = 2.31 ng/ml. A: T2WI imaging shows an area of intermediate 6 
signal with geographical features in the right mid/apex PZ (arrows) with no matching 7 
restricted diffusion (B,C). The region shows focal early enhancement on DCE-MRI (arrow in 8 
D), with a Type III curve. PI-RADS v1 scores: 2 for T2, 2 for DWI, 5 for DCE, summed score = 9 
9. PI-RADS v2 overall score 2 (DWI is the dominant PZ sequence) despite being “positive” for 10 
DCE. Targeted biopsy of this region was benign. 11 
 12 
 13 
Figure 4. False-negative DCE, correctly evaluated as likely tumour using PI-RADS v2 criteria  14 
60 year-old patient with a PSA of 4.48 ng/ml. A: T2WI imaging shows a focal area of 15 
intermediate/low signal the right mid/apex PZ (arrows), with marked matching restricted 16 
diffusion (B, C). The region shows diffuse, but no focal or early enhancement on DCE-MRI 17 
(arrow in D), with a Type I curve.  PI-RADS v1 scores: 3 for T2, 5 for DWI, 1 for DCE, summed 1 
score = 9. PI-RADS v2 overall score 5 (DWI is the dominant PZ sequence) despite being 2 
“negative” for DCE. Targeted biopsy demonstrated a Gleason 3+3 tumour in 10% of the 3 
cores. 4 
 5 
 6 
 7 
Figure 5. High b-value images aid detection of bone metastases 8 
68 year old with rising PSA, two years post prostatectomy. A: axial T2-weighted imaging 9 
shows a subtle low intensity area in the left acetabulum (arrow). B: Axial b-1400 diffusion-10 
weighted sequence; the lesion demonstrates restricted diffusion and appears more 11 
conspicuous on these high b-value images.  12 
 13 
 14 
 15 
Figure 6. Sector maps for division of prostatic regions  16 
PI-RADS v2 schema incorporating the central zone and utilizing alphabetic abbreviations; PZ 1 
= peripheral zone, TZ = transition zone, a = anterior, p = posterior, pm = postero-medial, pl = 2 
postero-lateral, AS = anterior stroma. Used with Permission David Rini ©, Johns Hopkins 3 
University . 4 
